Login to Your Account

Beigene moves BTK inhibitor to clinic, inks deal with BI

By Shannon Ellis
Staff Writer

Tuesday, September 9, 2014
SHANGHAI – Upstart Beigene Co. Ltd. wowed observers last year when it landed two deals with Merck Serono, a division of Merck KGaA, which licensed global rights to two of their preclinical oncology candidates for a combined value of close to $500 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription